NEA Management Company’s Adaptimmune Therapeutics ADAP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.09M | Hold |
|
|||||
|
2025
Q1 | $3.36M | Hold |
|
|||||
|
2024
Q4 | $9.2M | Hold |
|
|||||
|
2024
Q3 | $16.2M | Hold |
|
|||||
|
2024
Q2 | $16.7M | Hold |
|
|||||
|
2024
Q1 | $27M | Hold |
|
|||||
|
2023
Q4 | $13.5M | Hold |
|
|||||
|
2023
Q3 | $13.3M | Hold |
|
|||||
|
2023
Q2 | $15.8M | Sell |
|
|||||
|
2023
Q1 | $18.6M | Hold |
|
|||||
|
2022
Q4 | $24.9M | Sell |
|
|||||
|
2022
Q3 | $18.4M | Hold |
|
|||||
|
2022
Q2 | $29M | Buy |
|
|||||
|
2022
Q1 | $35.2M | Hold |
|
|||||
|
2021
Q4 | $64.1M | Hold |
|
|||||
|
2021
Q3 | $88.3M | Hold |
|
|||||
|
2021
Q2 | $72.8M | Hold |
|
|||||
|
2021
Q1 | $90.7M | Hold |
|
|||||
|
2020
Q4 | $92.1M | Hold |
|
|||||
|
2020
Q3 | $136M | Hold |
|
|||||
|
2020
Q2 | $171M | Hold |
|
|||||
|
2020
Q1 | $46.5M | Buy |
|
|||||
|
2019
Q4 | $19M | Hold |
|
|||||
|
2019
Q3 | $23.9M | Hold |
|
|||||
|
2019
Q2 | $63.6M | Hold |
|
|||||
|
2019
Q1 | $68.1M | Hold |
|
|||||
|
2018
Q4 | $91M | Hold |
|
|||||
|
2018
Q3 | $215M | Buy |
|
|||||
|
2018
Q2 | $158M | Hold |
|
|||||
|
2018
Q1 | $150M | Buy |
|
|||||
|
2017
Q4 | $80.3M | Hold |
|
|||||
|
2017
Q3 | $98.5M | Hold |
|
|||||
|
2017
Q2 | $54M | Hold |
|
|||||
|
2017
Q1 | $66.3M | Buy |
|
|||||
|
2016
Q4 | $40M | Hold |
|
|||||
|
2016
Q3 | $69.7M | Hold |
|
|||||
|
2016
Q2 | $80.5M | Hold |
|
|||||
|
2016
Q1 | $80.3M | Buy |
|